Zevra Therapeutics (ZVRA) Other Accumulated Expenses (2015 - 2026)

Zevra Therapeutics has reported Other Accumulated Expenses for 12 years, with the latest figure at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 58.6% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (down 58.6% YoY), and the FY2025 full-year result was $1.4 million, down 39.73% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $1.4 million, up from $1.4 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $9.0 million in Q3 2025, with the low at $311000.0 in Q3 2023.
• Historically, Other Accumulated Expenses has averaged $2.5 million across 5 years, with a median of $1.7 million in 2024.
• Annual changes were most pronounced in 2023 — Other Accumulated Expenses tumbled 75.19% — and 2025, when it jumped 866.67%.
• Zevra Therapeutics' Other Accumulated Expenses stood at $629000.0 in 2022, then surged by 301.27% to $2.5 million in 2023, then slipped by 10.46% to $2.3 million in 2024, then sank by 39.73% to $1.4 million in 2025, then grew by 3.38% to $1.4 million in 2026.
• The last three Other Accumulated Expenses figures came in at $1.4 million (Q1 2026), $1.4 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.